Dual CAR-T Therapies Are Becoming More Established
www.medscape.com
June 29, 2024, 6:58 a.m.
"There are still biological barriers to overcome. For example, three out of 10 patients receiving CAR-T therapy for relapsed/refractory large B-cell lymphoma fail because of antigen loss. Dual CAR-T therapies could overcome this resistance mechanism and increase efficacy. We have different strategies, such as tandem CAR-T cells, bicistronic CAR-T cells, cotransduction, and coadministration. Furthermore, there are ongoing studies like Zamto-cel, Prizlo.cel, AUTO3, KITE-363, and KITE-753. Some dual CAR constructs have shown positive results, but more work is needed."